➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Merck
Harvard Business School
Moodys
Dow

Last Updated: April 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DENUFOSOL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for Denufosol

Trial ID Title Status Sponsor Phase Summary
NCT00034515 A Study in Adult and Pediatric Patients With Cystic Fibrosis Completed Merck Sharp & Dohme Corp. Phase 1/Phase 2 The purpose of this ascending dose group study is to assess the safety, tolerability, and effects of multiple dose levels of INS37217 and placebo followed by five days twice daily treatment with maximum tolerated dose administered by inhalation via the Pari LC Star nebulizer in adult and pediatric patients with cystic fibrosis
NCT00056147 Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease Completed Cystic Fibrosis Foundation Therapeutics Phase 2 The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis (CF) lung disease. Study drug will be administered through a nebulizer (a device that delivers medication as a mist by breathing it in).
NCT00056147 Study of INS37217 Inhalation Solution in Mild to Moderate Cystic Fibrosis Lung Disease Completed Merck Sharp & Dohme Corp. Phase 2 The purpose of this study is to assess the safety and effectiveness of multiple dosages of INS37217 compared to placebo over 28 days in subjects with mild to moderate cystic fibrosis (CF) lung disease. Study drug will be administered through a nebulizer (a device that delivers medication as a mist by breathing it in).
NCT00083967 Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment Terminated Merck Sharp & Dohme Corp. Phase 2 The purpose of this study is to test if denufosol will remove the fluid build-up in the eye so that the retina can be re-attached without invasive surgery.
NCT00103714 Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease Completed Merck Sharp & Dohme Corp. Phase 2 The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of two dose levels of INS37217 (denufosol tetrasodium) Inhalation Solution in patients with cystic fibrosis (CF) lung disease.
NCT00114062 Study to Treat Uveitis Associated Macular Edema Terminated Merck Sharp & Dohme Corp. Phase 2 The purpose of this study is to determine whether denufosol tetrasodium (INS37217) Intravitreal Injection is well tolerated and has the potential to treat uveitis associated macular edema.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Denufosol

Condition Name

Condition Name for
Intervention Trials
Cystic Fibrosis 9
Retinal Detachment 2
Healthy 2
Uveitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Fibrosis 9
Cystic Fibrosis 9
Lung Diseases 6
Pulmonary Fibrosis 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Denufosol

Trials by Country

Trials by Country for
Location Trials
United States 60
Australia 6
Canada 6
New Zealand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
Ohio 2
Florida 2
Pennsylvania 2
North Carolina 2
Virginia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Denufosol

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 3
Phase 2 8
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 10
Terminated 4
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Denufosol

Sponsor Name

Sponsor Name for
Sponsor Trials
Merck Sharp & Dohme Corp. 15
Cystic Fibrosis Foundation Therapeutics 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 15
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Johnson and Johnson
Moodys
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.